Decoding the Brain for Tomorrow’s Treatments
At Inscopix, we seek to unlock human potential by developing advanced technologies and quantitative neural circuit-based approaches to understand the brain in health and to heal it in disease.
Positioned at the intersection of neuroscience, technology, and community, we work with stakeholders across sectors- academia, biopharmaceutical industry, philanthropy, and government- to catalyze and translate deep scientific insights into new therapies for people living with debilitating neurological and psychiatric illnesses such as depression, Parkinson’s, Alzheimer’s, and PTSD.
Mountain View, California
In 2016, Inscopix was ranked #61 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology and media companies in North America.
In 2015, the World Economic Forum recognized Inscopix as a Technology Pioneer, an honor that it bestows on a selection of the world’s most innovative young companies.
In 2014, the White House recognized Inscopix as an industry partner of the Presidential BRAIN Initiative. Inscopix supported the initiative through its $2 million DECODE Grant Program.
In 2013, The Scientist magazine ranked Inscopix’s miniature microscope as the #1 life science innovation, calling it a “major disruptive event in the history of neuroscience.”
Inscopix is founded by Drs. Kunal Ghosh, Mark Schnitzer, and Abbas El Gamal to commercialize the Stanford miniature microscope invention. The company receives seed financing from Floodgate and Fidelity Biosciences.
Inscopix launches nVista, a commercial grade miniature microscope-based brain imaging system for plug-and-play neural mapping at the Society for Neuroscience (SfN) Meeting.
First Systems Shipped
The first nVista Systems are sent to customers’ laboratories at Pfizer and the Howard Hughes Medical Institute (HHMI).
Building the infrastructure
Inscopix builds its manufacturing facility at the Mountain View headquarters and biological R&D labs in Mountain View for application development, training, and scientific research.
A growing user base
Inscopix community grows to over 100 laboratories across the globe. These include 6 Nobelists and 23 HHMI investigators. First research article outside the founders lab is published in the top-tier journal Cell.
The company launches a second product, nVoke System, for integrated brain activity imaging and manipulation at the annual SfN meeting.
The complete solution begins to form
Inscopix launches the nVista 3.0 System and the nVoke 2.0 System compatible with a new commutator. We also launched ready-to-image viruses and the Inscopix Data Processing Software (IDPS) towards offering users a complete workflow.
The user base expands to over 250 laboratories with over 425 Systems in the field. The Inscopix community publishes over 50 peer-reviewed original research articles in top-tier journals, with two publications using the nVoke System.
Translational efforts gather momentum
Inscopix launches two pharma collaborations with Biogen (in the area of chronic pain) and Astellas (in the area of psychiatric disorders). The first successful application of Inscopix platforms into non-human primate models is published.
Scientific Thought Leadership in a challenging year
The company rapidly transitions to an all-virtual thought leadership program for the socially and scientifically distanced neuroscience community, notably with the Insights Webinars and the DECODE 2020 Summit.
Inscopix launches the nVue System for dual-color miniscope imaging during free behavior, which is The Scientist’s #1 innovation for the year.